SA
Sign upLog In
BWAY

BrainsWay Ltd. specializes in non-invasive Deep TMS (Transcranial Magnetic Stimulation) technology for treating mental health disorders, particularly depression and OCD. Its competitive edge lies in proprietary technology that allows for targeted stimulation of specific brain areas, enhancing treatment efficacy in the U.S. and European markets.

HealthcareMedical - Devicesmoderate - The company has high gross margins (75.4%) but relatively low operating margins (8.3%), indicating potential for improved profitability as revenue scales.

Business Overview

01Device sales (approximately 60% of total revenue)
02Treatment sessions (approximately 30% of total revenue)
03Training and support services (approximately 10% of total revenue)

BrainsWay generates revenue primarily through the sale of its TMS devices to hospitals and clinics, alongside recurring revenue from treatment sessions. The company's pricing power is supported by its unique technology and clinical efficacy, which is backed by multiple studies demonstrating superior outcomes compared to traditional therapies.

What Moves the Stock

Regulatory approvals for new indications or devices

Clinical trial results demonstrating efficacy in new markets

Expansion of treatment centers adopting TMS technology

Partnerships with healthcare providers for broader distribution

Watch on Earnings
Device sales growthNumber of treatment sessions conductedNew clinic partnerships established

Risk Factors

Technological disruption from emerging mental health treatment modalities

Regulatory changes affecting device approval processes

Increasing competition from other TMS providers and alternative therapies

Potential market saturation in key regions

Limited cash flow generation (operating cash flow at $0.0B)

Dependence on continued investment for R&D and marketing

StructuralCompetitiveBalance Sheet

Macro Sensitivity

Economic Cycle

moderate - The demand for mental health treatments can be influenced by economic conditions, as consumer spending on healthcare may decline during downturns.

Interest Rates

Low - As a low-debt company (Debt/Equity of 0.09), rising interest rates have minimal impact on financing costs, although they could affect consumer spending on elective treatments.

Credit

minimal - The company operates with low debt levels, reducing reliance on credit markets.

Live Conditions
Russell 2000 FuturesDow Jones FuturesS&P 500 Futures

Profile

growth - The company is positioned for rapid revenue growth driven by increasing adoption of TMS technology.

high - The stock has shown significant volatility, with a 1-year return of 135.7% reflecting market sentiment and growth potential.

Key Metrics to Watch
Number of new clinics adopting TMS technology
Clinical trial outcomes for new indications
Revenue from treatment sessions

Explore More

Stock Comparison

Compare equities side by side

52-Week Highs Breakout

Stocks breaking to new annual highs

52-Week Lows Oversold

S&P 500 oversold value screener

Trending Momentum

Relative strength momentum leaders

Earnings Calendar

Upcoming earnings dates & reports

S&P 500 Screener

Filter and sort all 500 stocks

Strategy Focus List

Continuous multi-factor scoring & catalyst forensics

Market Movers

Today's biggest gainers and losers

Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.